🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12145944

Imidazopyrimidines as EED inhibitors and the use thereof

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12138263

Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof

Relay Therapeutics, Inc. · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12133849

Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting

Actinium Phamaceuticals, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12129262

CDK inhibitors and their use as pharmaceuticals

Prelude Therapeutics, Incorporated · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12129263

Kinase inhibitors and uses thereof

DENALI THERAPEUTICS INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128015

APE/REF1 inhibitors for the treatment of cancer

The Regents of the University of California · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128048

Combination therapies using PRMT5 inhibitors for the treatment of cancer

Mirati Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12122773

Crystalline hydrate of a JAK inhibitor compound

Theravance Biopharma R&D IP, LLC · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121540

CBL inhibitors and compositions for use in adoptive cell therapy

NURIX THERAPEUTICS, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121522

Methods of treating cancer with an mTOR inhibitor

Revolution Medicines, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12123001

Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121524

DNA-PK inhibitors

Vertex Pharmaceuticals Incorporated · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115156

Compositions of CXCR4 inhibitors and methods of preparation and use

X4 Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115163

Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor

IDEAYA Biosciences, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116354

RIP1 inhibitory compounds and methods for making and using the same

Rigel Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116343

Inhibitors of APOL1 and methods of using same

Vertex Pharmaceuticals Incorporated · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116346

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12103907

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

Arcus Biosciences, Inc. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097213

Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation thera

The Board of Regents of the University of Texas System · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097262

mTORC1 inhibitors

The Regents of the University of California · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097210

Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

Corcept Therapeutics Incorporated · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097199

Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies

Takeda Pharmaceutical Company Limited · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12084438

GCN2 inhibitors and uses thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12083137

Triazole bisphosphonate geranylgeranyl diphosphate synthase inhibitors

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted